|
WO2016168440A1
|
|
Methods for treating lung cancer
|
|
BR112015031950A2
|
|
Methods for Ovarian Cancer Treatment
|
|
BR112015022085A2
|
|
methods for assessing colorectal cancer prognosis
|
|
WO2013172951A1
|
|
Methods for treatment of gastric cancer
|
|
WO2013003507A1
|
|
Multifunctional agents
|
|
EP2680839A1
|
|
Co -administration of eribulin and farletuzumab for the treatment of breast cancer
|
|
WO2012050883A1
|
|
Engineered human endosialin-expressing rodents
|
|
CN102844044A
|
|
Chlorotoxin polypeptides and conjugates and uses thereof
|
|
US2010260769A1
|
|
Endosialin binding molecules
|
|
EP2310416A1
|
|
Anti-gd2 antibodies and methods and uses related thereto
|
|
CN101918446A
|
|
Methods for inhibiting the binding of endosialin to ligands
|
|
EP3138852A1
|
|
High affinity antibodies that neutralize staphylococcus enterotoxin b
|
|
AU2007237985A1
|
|
Whole genome evolution technology applied to improve protein and antibody yields by cells
|
|
EP1885860A2
|
|
Regulated vectors for selection of cells exhibiting desired phenotypes
|
|
US2006068497A1
|
|
Methods for isolating novel antimicrobial agents from hypermutable mammalian cells
|
|
CA2556027A1
|
|
Monoclonal antibodies that specifically block biological activity of a tumor antigen
|
|
CA2548813A1
|
|
Antibodies that specifically bind pms2
|
|
US7604994B2
|
|
Genetically altered antibody-producing cell lines with improved antibody characteristics
|
|
WO2005014652A1
|
|
A variant cell surface molecule associated with cancer
|
|
WO2005011735A1
|
|
Antibodies and methods for generating genetically altered antibodies with enhanced effector function
|
